Comparing of intravenous treatment with dexmedetomidine and ketamine in bipolar disorder

Comparing the effect of intravenous treatment with dexmedetomidine and ketamine in controlling agitation in patients with bipolar disorder

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20251123068088N1

Enrollment

162

Registered

2025-12-02

Start date

2025-12-21

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar disorder. Bipolar disorder

Interventions

Intervention 1: First intervention group: 81 patients will be treated with intravenous infusion of dexmedetomidine (trade name Medonex - Exir - Iran) at a rate of 0.5 µg/kg/hour for one hour. The pati

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Age between 18 and 60 years old

Exclusion criteria

Exclusion criteria: Allergy to anesthetic drugs Presence of a substance abuse disorder Pregnancy or breastfeeding

Design outcomes

Primary

Measure	Time frame
Agitation rate. Timepoint: 15 minutes before and one hour after the start of the intervention. Method of measurement: The Positive and Negative Syndrome Scale.	—

Secondary

Measure	Time frame
Presence of vomiting. Timepoint: 15 minutes before and one hour after the start of the intervention. Method of measurement: Clinical history.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Gholinejad

Arak University of Medical Sciences

Mrymg2000@gmail.com+98 86 3457 3308

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026